The Research Laboratory of the Center for Expertise of Rare Hematological Diseases of Children and Adults – Cutaneous Lymphoma with the Head of the Laboratory Dr. Karagianni Fani, in collaboration with the 2nd Propaudeutic Pathological Clinic, University Hospital ATTIKO and with the supervision of the supervising Professors of EKPA, Hematology Dr. Pappa Vasiliki, Clinical Biochemistry, Dr. Piperi Christina and Dermatology Dr. Evangelia Papadavid, has developed protocols at research level in which the research aims at discoveries that will help the clinical application.
Our research protocols (European, corporate) and our work are published in peer-reviewed journals. It is worth noting that the Research Laboratory of Center for Expertise of Rare Hematological Diseases of Children and Adults – Cutaneous Lymphoma is the recipient of funding for the “1st Open Call for the provision of free personalized research services” from the pMedGR research infrastructure entitled “The role of environment of different cell population in a tool for identifying biomarkers for disease progression and individualized therapy ”(CyTOF), a proposal which was selected from 35 proposals of the highest scientific interest and quality of National and Kapodistrian University of Athens (NKUA).
Briefly, our research interest focuses on the investigation of possible mechanisms involved in the pathogenesis of Cutaneous T cell lymphoma:
- The effect of inhibitors (JAK / STAT, HDAC, etc.) on Cutaneous Lymphoma
- The role of the microenvironment in cutaneous T-cell lymphomas (research proposal pMEDgr)
- Determine the profile of gene expression in patients with cutaneous T-cell lymphoma
- Finding new biomarkers for the early prognosis of cutaneous lymphoma and the differential diagnosis from other inflammatory skin diseases
The aim and priority of our research activity is to highlight appropriate tools – biomarkers for early diagnosis, valid differential diagnosis of other inflammatory skin diseases, anticipation for response to treatment and planning new personalized treatments.
- Impact of Circulating miRNAs in Cutaneous T-cell Lymphoma Diagnosis: miR-146a and miR-26a as Promising Diagnostic Biomarkers. Marianna Papadaki, Christina Piperi, Georgia Damoraki and Evangelia Papadavid, Acta Scientific Medical Sciences.2022; 6 (4): 90-99.
- Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma. Karagianni F, Piperi C, Casar B, de la Fuente-Vivas D, García-Gómez R, Lampadaki K, Pappa V, Papadavid E. Cancers. 2022; 14(4):1070. https://doi.org/10.3390/cancers14041070
- Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential., Karagianni, F., Pavlidis, A., Malakou, L.S., Piperi, C., Papadavid E., Int. J. Mol. Sci. 2022, 23, 1693. https://doi.org/10.3390/ijms23031693
- Chlormethine Gel in Combination with Other Therapies in the Treatment of Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: Three Case Reports. Lampadaki K, Koumourtzis M, Karagianni F, Marinos L, Papadavid E. Adv Ther. 2021 Jun;38(6):3455-3464. doi: 10.1007/s12325-021-01721-x. Epub 2021 Apr 30. PMID: 33928511;
- Novel therapeutic approaches for Cutaneous T cell lymphomas.
Expert Rev Clin Immunol. 2021 Apr 23. doi: 10.1080/1744666X.2021.1919085
- Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.
PLoS One. 2021 Mar 11;16(3):e0248298. doi: 10.1371/journal.pone.0248298. eCollection 2021
- Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1.
Exp Ther Med. 2021 Mar;21(3):195. doi: 10.3892/etm.2021.9628. Epub 2021 Jan 8.
- Cutaneous T-cell lymphoma: aetiopathogenesis and current diagnostic and therapeutic developments.
Eur J Dermatol. 2020 Apr 16. doi: 10.1684/ejd.2020.3712